

Spencer W. Vaughan

Associate Attorney

svaughan@gibsondunn.com

T: +1 332.253.7741

Dallas



Spencer W. Vaughan is an associate in Gibson Dunn's Dallas office.

Spencer received his Juris Doctor from Harvard Law School in 2023. At Harvard, Spencer was a J.D./Ph.D. student, with the Ph.D. program being in Biological and Biomedical Sciences at Harvard University. In lieu of pursuing a thesis, he paused the Ph.D. after completing Year 1 in good academic standing to pursue a J.D. at Harvard Law School. Spencer has contributed as a co-author to several scientific research articles relating to biological pathways underlying neurological diseases and immunological disorders. These articles have been published in *Nature Neuroscience*, *Nature Genetics*, *Nature Communications*, etc.

Spencer received his Bachelor of Science in Neuroscience and Molecular Biology, *summa cum laude*, from the University of Arizona in 2017. Prior to attending law school, Spencer was a biological research scientist working in the areas of neuroscience and immunology.

Spencer has litigated in federal District Courts and the U.S. Patent & Trademark Office (PTO). Spencer has experience in pre-suit diligence, Rule 12 motions, fact discovery, deposition preparation, expert discovery, claim construction, dispositive motions and hearings, bench trials, and pre- and post-trial briefing.

Spencer is admitted to practice in the State of New York and Texas.

Representative Matters:

- Represented Cassava Sciences in the Western District of Texas in a securities class action suit.
- Represented Cassava Sciences in SEC and DOJ investigations.
- Represented Novartis in the District of Delaware against generic manufacturers of a leading drug indicated for acute myeloid leukemia.
- Represented Novartis in the District of Delaware against generic manufacturers of a leading drug indicated for gastroenteropancreatic neuroendocrine tumors.
- Represented Novartis in trade secret litigation in the District of Delaware regarding leading drug indicated for gastroenteropancreatic neuroendocrine tumors.
- Represented Vifor (International) AG and American Regent in multiple suits in the District of New Jersey and District of Delaware against generic manufacturers of a leading drug indicated for iron deficiency anemia.
- Represented NeoGenomics in the PTO regarding methods for monitoring cancer using cell-free DNA.

Publications:

Capabilities

Intellectual Property
Antitrust and Competition
Class Actions
FDA and Health Care
Life Sciences
Litigation
Securities Litigation
Technology Litigation
Trials

Credentials

Education

Harvard University - 2023 Juris Doctor
University of Arizona - 2017 Bachelor of Science

Admissions

New York Bar
Texas Bar

- Co-Author, "[Mutations disrupting neuritogenesis genes confer risk for cerebral palsy](#)," *Nature Genetics* (September 28, 2020)
- Co-Author, "[Opposing peripheral fates of tissue-restricted self antigen-specific conventional and regulatory CD4+ T cells](#)," *European Journal of Immunology* (October 3, 2019)
- Co-Author, "[TSC2-deficient tumors have evidence of T cell exhaustion and respond to anti-PD-1/anti-CTLA-4 immunotherapy](#)," *JCI Insight* (April 19, 2018)
- Co-Author, "Minimally Invasive Spinal Surgery, Principles and Evidence-Based Practice, Ch. 28, Indications for and benefits of lumbar spinal hardware removal," *JP Medical Publishers* (February 1, 2018)
- Co-Author, "[TDP-43 pathology disrupts nuclear pore complexes and nucleocytoplasmic transport in ALS/FTD](#)," *Nature Neuroscience* (January 8, 2018)
- Co-Author, "[Endocytosis regulates TDP-43 toxicity and turnover](#)," *Nature Communications* (December 12, 2017)

**Spencer W.
Vaughan**
Associate Attorney

svaughan@gibsondunn.com

T: +1 332.253.7741

Dallas